These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 5783335)

  • 21. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Atypical myeloproliferative disorders: a study on 3 cases showing pancytopenia, marrow fibrosis and the absence of splenomegaly].
    Yoshida Y; Yamagishi M; Fukuhara S; Sawada H; Ohkuma M; Uchino H; Nakamura T
    Rinsho Ketsueki; 1984 Mar; 25(3):383-92. PubMed ID: 6471435
    [No Abstract]   [Full Text] [Related]  

  • 24. [Vascular changes in bone marrow in blood diseases].
    Demmler K; Burkhardt R
    Med Klin; 1980 Apr; 75(9):328-32. PubMed ID: 7402170
    [No Abstract]   [Full Text] [Related]  

  • 25. [Chronic myeloproliferative diseases].
    Verh Dtsch Ges Pathol; 1983; 67():214-75. PubMed ID: 6666266
    [No Abstract]   [Full Text] [Related]  

  • 26. [Osteomyelofibrosis as a prognostic factor in myeloproliferative diseases?].
    Wehmeier A; Schneider W
    Dtsch Med Wochenschr; 1993 May; 118(21):804-5. PubMed ID: 8504717
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only.
    Brubaker LH; Brière J; Laszlo J; Kraut E; Landaw SA; Peterson P; Goldberg J; Donovan P
    Arch Intern Med; 1982 Aug; 142(8):1533-7. PubMed ID: 7103635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
    Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
    Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Unusual case of chronic myeloproliferative syndrome].
    Tosato F; Fossaluzza V
    Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hemostasis disorders with reduced activity of the von Willebrand factor in myeloproliferative syndromes].
    Leupin L; Beck EA; Furlan M; Bucher U
    Schweiz Med Wochenschr; 1983 May; 113(19):713-6. PubMed ID: 6603016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Platelet defects in chronic myeloproliferative disorders].
    Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
    Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism.
    Hasselbalch HC
    Dan Med Bull; 1993 Mar; 40(1):39-55. PubMed ID: 8472598
    [No Abstract]   [Full Text] [Related]  

  • 37. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
    Zhang SJ; Li JY
    Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
    [No Abstract]   [Full Text] [Related]  

  • 38. Chromosome abnormalities in the myeloproliferative disorders.
    Dewald GW; Wright PI
    Semin Oncol; 1995 Aug; 22(4):341-54. PubMed ID: 7638632
    [No Abstract]   [Full Text] [Related]  

  • 39. Myeloproliferative diseases in childhood.
    Nix WL; Fernbach DJ
    Am J Pediatr Hematol Oncol; 1981; 3(4):397-407. PubMed ID: 6174053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chronic myeloproliferative syndromes].
    de Ozalla CB; García Suárez J
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():28-36. PubMed ID: 10422448
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.